BARBARA HERRING: Open Payments
NPI 1699401760 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,396 in 76 payments from 30 companies in 2025. Trend: 2023 $266 · 2024 $1,032 · 2025 $1,396
Food & beverage: $1,396
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $149 |
| Incyte Corporation | 12 | $138 |
| Merck Sharp & Dohme LLC | 6 | $135 |
| Novartis Pharmaceuticals Corporation | 6 | $107 |
| AstraZeneca Pharmaceuticals LP | 5 | $90 |
| Daiichi Sankyo Inc. | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Alexion Pharmaceuticals, Inc. | 2 | $47 |
| BeOne Medicines USA, Inc. | 2 | $43 |
| Genentech USA, Inc. | 2 | $42 |
Products named: KEYTRUDA, RYBREVANT, JAKAFI, VENCLEXTA, MONJUVI, TECVAYLI, Enhertu, ULTOMIRIS.
Industry payments across MS — which companies pay providers there.
